Rapid growth continues for Sistemic

"ON TOP OF THE WORLD"

12 January 2012: Sistemic, UK:  Sistemic, the stem cell and drug development technology company, has won a substantial Scottish Regional Selective Assistance (RSA) grant from Scottish Enterprise. The grant forms part of a £1M planned investment programme which, on the back of a very successful year for the company, will see Sistemic more than double the size of its operation. To accommodate the expanded  research team, the company is relocating to customised laboratories during the first half of 2012.

Jim Reid, Sistemic ‘s Chairman and CEO said, “Securing this support from Scottish Enterprise is a major achievement and shows great support by the Scottish Government for what we are doing. It adds to an already successful year for Sistemic, a year which has seen us grow sales dramatically and develop our customer base in Europe, USA, Japan and Australia. We truly have become a global company during 2011 and we look forward to relocating in the first half of 2012 to allow this success and growth to continue. It is always an exciting opportunity to be on the lookout for new employees and we are ideally placed to recruit top talent. This type of grant support is crucial to help grow successful research focused biotech companies such as ours and we will ensure we make the most of it!”

“We work very closely with some of the world’s leading stem cell and pharmaceutical companies and we need to continually review our operations to make sure that we have the best technology and services and we need a facility which suits our needs,” explains Reid. “The world is waking-up to the incredible opportunities offered by stem cell technology. Opportunities which show great promise to prolong healthy life and Sistemic is already a key part of this burgeoning worldwide industry.”

Sistemic‘s SistemRNA™, SistemQC™, SistemKB™  and SistemTOX™ products have brought new depth to miRNA analysis, which has been shown to add value to drug discovery, cell therapeutics and diagnostics.  For 2012 the company looks forward to increased business and growing their client network around the world.

For further information on Sistemic and Sistemic miRNA analysis products, please visit: www.sistemic.co.uk

Regional Selective Assistance (RSA) is the main investment grant scheme in areas of Scotland designated for regional aid under European Community law. RSA funding is available to create or safeguard jobs for both Scottish owned businesses and inward investors. For further information visit the Scottish Development International website: http://www.sdi.co.uk/

                                                                         End